Eligo Bioscience
Signal active
Organization
Contact Information
Overview
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
About
Industries
Biotechnology, Health Care, Medical
Founded
2014
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
Eligo Bioscience headquartered in Europe, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $7.5B in funding across 108 round(s). With a team of 11-50 employees, Eligo Bioscience is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Eligo Bioscience, raised $2.9M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
9
Investors
2
Lead Investors
0
Total Funding Amount
$69.7M
Details
4
Eligo Bioscience has raised a total of $69.7M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2015 | Seed | |||
| 2023 | Early Stage Venture | 29.9M | ||
| 2017 | Early Stage Venture | 18.0M | ||
| 2015 | Seed | 2.9M |
Investors
Eligo Bioscience is funded by 23 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Khosla Ventures | - | FUNDING ROUND - Khosla Ventures | 18.0M |
| Eligo Bioscience | - | FUNDING ROUND - Eligo Bioscience | 18.0M |
| Seventure Partners | - | FUNDING ROUND - Seventure Partners | 18.0M |
| Eligo Bioscience | - | FUNDING ROUND - Eligo Bioscience | 2.9M |
Recent Activity
There is no recent news or activity for this profile.